Table 3

TEAEs by SOC and PT

TEAEs (any TEAE ≥2.5% in any treatment group)—n (%)Brodalumab 210 mg
N=80
Placebo
N=79
Infections and infestations18 (22.5)15 (19.0)
 Nasopharyngitis8 (10.0)9 (11.4)
 Rhinitis3 (3.8)1 (1.3)
 Upper respiratory tract infection2 (2.5)5 (6.3)
Gastrointestinal disorders13 (16.3)7 (8.9)
 Diarrhoea3 (3.8)1 (1.3)
 Mouth ulceration3 (3.8)1 (1.3)
 Abdominal pain upper2 (2.5)0
 Vomiting2 (2.5)0
Investigations7 (8.8)1 (1.3)
 Alanine aminotransferase increased4 (5.0)1 (1.3)
 Aspartate aminotransferase increased4 (5.0)1 (1.3)
 Liver function test abnormal2 (2.5)0
Musculoskeletal and connective tissue disorders6 (7.5)6 (7.6)
 Back pain02 (2.5)
Injury, poisoning and procedural complications5 (6.3)6 (7.6)
 Ligament sprain1 (1.3)2 (2.5)
Metabolism and nutrition disorders4 (5.0)2 (2.5)
Nervous system disorders3 (3.8)2 (2.5)
Skin and subcutaneous tissue disorders3 (3.8)5 (6.3)
 Pruritus2 (2.5)1 (1.3)
General disorders and administration site conditions2 (2.5)6 (7.6)
 Fatigue1 (1.3)2 (2.5)
Respiratory, thoracic and mediastinal disorders2 (2.5)3 (3.8)
Vascular disorders2 (2.5)2 (2.5)
 Hypertension2 (2.5)2 (2.5)
  • PT, preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event.